Tag Archives: Liana Moussatos

Wedbush Sticks to Their Buy Rating for Liquidia Technologies (LQDA)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Liquidia Technologies (LQDA – Research Report), with a price target of $38.00. The company’s shares closed last Monday at $7.88. According to TipRanks.com, Moussatos is a

Wedbush Sticks to Their Buy Rating for ObsEva SA (OBSV)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on ObsEva SA (OBSV – Research Report), with a price target of $30.00. The company’s shares closed last Monday at $3.25. According to TipRanks.com, Moussatos is a

Wedbush Sticks to Their Buy Rating for Aquestive Therapeutics (AQST)

Wedbush analyst Liana Moussatos maintained a Buy rating on Aquestive Therapeutics (AQST – Research Report) yesterday and set a price target of $31.00. The company’s shares closed last Thursday at $4.71. According to TipRanks.com, Moussatos is a 5-star analyst with

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Esperion (NASDAQ: ESPR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND – Research Report) and Esperion (ESPR – Research Report) with bullish sentiments. Ascendis Pharma (ASND) In a report released

Wedbush Reiterates a Buy Rating on Miragen Therapeutics (MGEN)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Miragen Therapeutics (MGEN – Research Report) today and set a price target of $6.00. The company’s shares closed last Tuesday at $1.22. According to TipRanks.com, Moussatos is a 5-star analyst with

Wedbush Reiterates a Buy Rating on Immunic (IMUX)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Immunic (IMUX – Research Report) today and set a price target of $58.00. The company’s shares closed last Tuesday at $11.61. According to TipRanks.com, Moussatos is a 5-star analyst with an